Impact of hepatitis b virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages 1268-1273

  Idoko, John ^a   Meloni, Seema ^b   Muazu, Mohammed ^a   Nimzing, Ladep ^a   Badung, Bitrus ^a   Hawkins, Claudia ^c   Sankalé, Jean Louis ^b   Ekong, Ernest ^b   Murphy, Robert ^c   Kanki, Phyllis ^b   Thio, Chloe L ^d  

^a UNIVERSITY OF JOS   (Nigeria)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NIGERIA; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HIV INFECTIONS; HUMANS; MALE; NIGERIA; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70349902495     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605675     Document Type: Article

References (22)

1. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis virases and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:2125-2132 (Pubitemid 35168221)
2. Omland LH, Weis N, Skinhoj P et al. Impact of hepatitis B virus coinfection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med 2008;9:300-306
3. Law WP, Duncombe CJ, Mahanontharit A et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-1177 (Pubitemid 38738516)
4. Hoffmann CJ, Charalambous S, Martin DJ et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-1485
5. Iwalokun BA, Hodonu SO, Olaleye BM, Olabisi OA. Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria. Afr J Med Med Sci 2006; 35: 337-343
6. OtegbayoJA,TaiwoBO,AkingbolaTS,etal. PrevalenceofhepatitisBandCseropositivityinaNigeriancohortofHIV-infectedpatients. AnnHepatol2008;7:152-156(Pubitemid351845527)
7. Ejele OA, Nwauche CA, Erhabor O. The prevalence of hepatitis B surface antigenaemia in HIV positive patients in the Niger Delta Nigeria. Niger J Med 2004; 13:175-179
8. Nwokedi EE, Emokpae MA, Dutse AL Human immunodeficiency virus and hepatitis B virus co-infection among patients in Kano Nigeria. Niger J Med 2006; 15:227-229
9. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, Cha SS. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 2009;21:70-77
10. + lymphocyte levels in the highly HIV infected population of North-Central Nigeria. Mem Inst Oswaldo Cruz 2007; 102:535-537
11. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686 (Pubitemid 43374518)
12. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
13. You J, Sriplung H, Geater A, et al. Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulations in chronic HBV-infected individuals with normal liver function tests. World J Gastroenterol 2008; 14:3710-3718
14. Kotmire S, Gupta I, Ganguly NK, Koicha M. Study of T-lymphocyte subpopulation in HBsAg-positive pregnant women. Acta Virol 1993; 37:459-465
15. You J, Sriplung H, Geater A, et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8:123.
16. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AL Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009;81:441-445
17. Seto E, Yen TS, Peterlin BM, Ou JH. Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci USA 1988;85:8286-8290 (Pubitemid 18272119)
18. TwuJS,ChuK,RobinsonWS.HepatitisBvirusXgeneactivateskappaB- likeenhancersequencesinthelongterminalrepeatofhumanimmunodeficiencyvirus1. ProcNatlAcadSciUSA1989;86:5168-5172(Pubitemid19182255)
19. TwuJS,RosenCA,HaseltineWA,RobinsonWS. Identificationofaregionwithinthehuman immunodeficiencyvirustype1longterminalre peatthatisessentialfortransactivationbythehepatitisBvirusgeneX.JVirol1989;63: 2857-2860(Pubitemid19137569)
20. Nakamura K, Yuh K, Sugyo S, Shijo H, Kimura N, Okumura M. Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Gastroenterology 1996;111:156-164 (Pubitemid 26226895)
21. Raptopoulou-Gigi M, Orphanou-Koumerkeridou H, Lagra F. Possible mechanisms underlying peripheral lymphocyte activation in chronic liver disease and asymptomatic HBsAg carriers. Allergol Immunopathol (Madr) 1989;17:145-148
22. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510-1518 (Pubitemid 47274591)